Singleton J Matthew's Form 4 filing
Viking Therapeutics, Inc. (VKTX) · filed Oct 25, 2024
- Accession no.
- 0000950170-24-117513
- Filed
- Oct 25, 2024
- Trade date
- Oct 25, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.27M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Singleton J MatthewCIK 0001243514 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2024 | Common Stock, par value $0.00001 per share | MOption exerciseAcquired | +16,000 | $4.48 | +$71,680 | 25,500 | Direct | |
| Oct 25, 2024 | Common Stock, par value $0.00001 per share | SSaleDisposed | −16,000 | $79.50 | −$1,272,000 | 9,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2024 | Common Stock | MOption exerciseDisposed | −16,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.